| |
Pharmacokinetics of MK-8742, an HCV NS5A Inhibitor,
Following Single and Multiple Oral Doses of MK-8742 in Healthy Subjects
|
| |
| |
Reported by Jules Levin
AASD 2013 Nov 1-4 Wash DC
Eric Mangin,1 Luzelena Caro,1 Concetta Lipardi,1 Anna Mitselos,1 Wendy W. Yeh,1 Iain Fraser,1 Patricia Jumes,1 Xiaobi Huang,1 Daniel Dreyer,1L. Van Bortel,2 Joan R. Butterton1
1Merck & Co, Inc, Whitehouse Station, NJ, USA; 2Drug Research Unit, Ghent, Belgium
AASLD: Efficacy and Safety of an Interferon-Free Regimen of MK-5172 + Ribavirin for 12 Weeks or 24 Weeks in Treatment-Naive, Noncirrhotic Subjects With HCV GT1 Infection: The C-SPIRIT Study - (11/04/13)
AASLD: High Efficacy and Safety of the All-Oral Combination Regimen, MK-5172 / MK-8742 ± RBV for 12 Weeks in HCV Genotype 1 Infected Patients: The C-WORTHY Study - (11/05/13)
AASLD: Resistance Analysis [and activity] of Genotype-1 and -3 HCV-Infected Patients Receiving MK-8742, an HCV NS5A Inhibitor With Potent Antiviral Activity, in a Ph1b Monotherapy Study - (11/05/13)
|
|
| |
| |
|
|
|
